However, the cost of zuranolone makes it challenging to access and justify, given study results comparing it with brexanolone.
The future of vancomycin dosing lies in optimizing dosing regimens to individual patient needs.
Collaboration between AI-based platforms and health care organizations offers promising results.
Implementing these standards can be logistically challenging.
Interventions to improve medication adherence may have a greater impact on individual patients and the population as a whole than any novel treatment or therapy.
Pharmacists are uniquely positioned to play a frontline role in advancing health equity. This will require, however, that we build the pipeline of future pharmacists and preserve vital community touchpoints.
Routinely celebrating their work contributions and dedication adds value to your organization.
This medication is associated with a number of adverse effects, such as gastrointestinal upset and peripheral neuropathies, that may be mitigated by less frequent dosing.
Support from pharmacy management and increased job satisfaction for pharmacy technicians can improve medication therapy management programs.
Approved by the FDA in 2021, finerenone is the only non-steroidal mineralocorticoid receptor antagonist that reduces the risk of renal disease progression and cardiovascular events in adults with type 2 diabetes mellitus-mediated chronic kidney disease.
Preclinical data showed that LP-184 shrunk tumors in vivo by more than 90% in just 8 weeks.
In 2025, medically integrated dispensing pharmacies face significant challenges, including low reimbursements, restrictive pharmacy benefit manager practices, complex therapies, regulatory barriers such as the Stark delivery law, and the Inflation Reduction Act's financial implications, necessitating urgent advocacy, reform, and collaboration to sustain equitable, patient-centered cancer care.
Pharmacy workflow changes in the preparation of chemotherapy products can reduce patient chair time.
With a better understanding of the underlying pathophysiology of chronic lymphocytic leukemia and the introduction of novel targeted agents, such as Bruton kinase Inhibitors, the prognosis of high-risk patients has changed dramatically.
Offering individual advice and counseling to patients can help combat the risks of driving under the influence of prescription drugs.
AI-enabled remote cardiac telemetry can help manage stress’s effects on high-risk populations.
Although COVID-19 paused our original plans, we were ultimately able to reach more people than we ever could have via in-person presentations alone.
Measures like hassle-free safe sharps disposal packaging save critical staff time and resources.
TXNIP inhibition could prevent beta cell loss and protect beta cell function to potentially contribute to diabetes management and its complications.
Providers who are sensitive to health literacy have contributed to positive quality improvement across various institutions.
PBM reforms and regulatory changes have reshaped the industry landscape.
The SHARE model from the CDC involves personalizing recommendations for patients and their needs, addressing any concerns they may have, and explaining the risks of remaining unvaccinated.
Both benefits and concerns exist, but implementing policies and regulations promotes employee productivity, guards safety.
Educational programming for pharmacy students and practicing pharmacists on medication abortion is limited.
When it comes to vaccination efforts, remember that patients 65 years or older are not a homogeneous group.
As evidence for omega-3 continues to develop, pharmacists remain poised to guide patients toward the most indicated, safe, effective, and convenient options available.
Pharmacists are pivotal in expanding reproductive health care access through patient education and collaboration.
BRAF V600E inhibitors show improved outcomes in relapsed/refractory hairy cell leukemia.
An overview of how gene therapy has evolved since its inception, current applications, and emerging challenges.
Study finds little evidence to support the long-standing recommendation that women with a first-degree family relative diagnosed with breast cancer should get screened 10 years earlier.